Veracyte, Inc. (VCYT)
NASDAQ: VCYT · Real-Time Price · USD
34.98
+0.67 (1.95%)
Nov 4, 2024, 4:00 PM EST - Market closed
Veracyte Revenue
Veracyte had revenue of $114.43M in the quarter ending June 30, 2024, with 26.69% growth. This brings the company's revenue in the last twelve months to $399.58M, up 21.59% year-over-year. In the year 2023, Veracyte had annual revenue of $361.05M with 21.76% growth.
Revenue (ttm)
$399.58M
Revenue Growth
+21.59%
P/S Ratio
6.50
Revenue / Employee
$490,281
Employees
815
Market Cap
2.69B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 361.05M | 64.52M | 21.76% |
Dec 31, 2022 | 296.54M | 77.02M | 35.09% |
Dec 31, 2021 | 219.51M | 102.03M | 86.85% |
Dec 31, 2020 | 117.48M | -2.89M | -2.40% |
Dec 31, 2019 | 120.37M | 28.36M | 30.82% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
QuidelOrtho | 2.83B |
Amneal Pharmaceuticals | 2.60B |
Evolent Health | 2.35B |
Astrana Health | 1.59B |
LivaNova | 1.24B |
LifeStance Health Group | 1.16B |
Catalyst Pharmaceuticals | 434.48M |
TransMedics Group | 401.09M |
VCYT News
- 5 days ago - Veracyte to Participate in Upcoming Investor Conferences - Business Wire
- 19 days ago - Veracyte to Release Third Quarter 2024 Financial Results on November 6, 2024 - Business Wire
- 7 weeks ago - New Data Presented at ESMO 2024 Show that Veracyte's Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer - Business Wire
- 2 months ago - Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors - Business Wire
- 2 months ago - Veracyte to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference - Business Wire
- 2 months ago - Veracyte Named a Greater Bay Area Top Workplace by the San Francisco Chronicle - Business Wire
- 3 months ago - Diagnostic Tests Maker Veracyte's Q2 Is 'All-Around Very Good Quarter': Analysts Maintain Bullish View - Benzinga
- 3 months ago - Veracyte, Inc. (VCYT) Q2 2024 Earnings Call Transcript - Seeking Alpha